Fig. 4: Subtype-specific response (CR/PR) rates of PD-L1 blockade therapy, PD-L1 expression levels, and survival in the IMvigor210 cohort. | Communications Biology

Fig. 4: Subtype-specific response (CR/PR) rates of PD-L1 blockade therapy, PD-L1 expression levels, and survival in the IMvigor210 cohort.

From: Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy

Fig. 4

a Response rates, b PD-L1 expression levels, and c KM survival curves of the G3High and G3Low groups. d Response rates, e PD-L1 expression levels, and f KM survival curves of the G3High and G3Low groups in the basal and luminal sub-cohorts. g Response rates, h PD-L1 expression levels, and i KM survival curves of the immune cell (IC) subgroups. j Response rates, k PD-L1 expression levels, and l KM survival curves of the tumor-immune phenotypes. m Response rates, n PD-L1 expression levels, and o KM survival curves of the Lund subtypes. Fisher exact test was used to compare the CR/PR frequencies; t-test or ANOVA was used to compare PD-L1 expression between the subtypes. Log-rank test was used to compare subtype-specific survival curves.

Back to article page